Home > News / Events
Evry, Monday, April 15, 2013 – IntegraGen, today announced its financial results for the fiscal year ending December 31, 2102. The accounts were examined during the meeting of the Board of Directors held on April 11, 2013.2012 Annual Results
Lab21 and IntegraGen partner to develop new colorectal cancer diagnostic
Cambridge,UK –22nd February 2013 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics, has entered into an agreement with IntegraGen, to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.
see more >Press Release Lab21 Ltd.
Evry, 11th of February 2013 - IntegraGen announces today its sales for the year ending December 31st, 2012.
Continued growth of the genomic services, first sales of autism risk assessment in the USA
After an outstanding 2011 which showed a 45% growth in sales of genomic services, IntegraGen has continued its development with revenues of 4.75 M€, up 2.1% and bookings up 15%, compared to 2011.Revenue 2012
Bernard Courtieu, CEO at IntegraGen, will speak at next Autism Investment conference on Feb. 21st 2013 in New York.
IntegraGen announced today the formation of a Community Advisory Panel to provide the company with insight and feedback on planned educational materials and informational programs directed towards the autism community.
A new publication entitled "Parental Interest in a Genetic Risk Assessment Test for Autism Spectrum Disorders," has been published online in the journal of Clinical Pediatrics.
30 Oct. 2012 : IntegraGen released its 1st Semester results 2012, as approved by Board of Directors on Oct. 29th.
Major points :Stable Genomic services activities. Commercial launch of a predictive familial autism test in USA.IntegraGen Half Year results 2012
The Knights of Columbus Developmental Center at SSM Cardinal Glennon Children's Medical Center in St. Louis, Missouri is conducting a study with the ARISk Test.
IntegraGen announced that the company has received €2 millions in financing from funds managed by A Plus Finance. The funds will be used to support the company's efforts with biomarker development for colorectal and liver cancer and develop/commercialization efforts in the field of autism molecular diagnostics.
IntegraGen announced today the presentation of scientific data which demonstrates the role of common genetic variants towards the identification of risk of autism in siblings of children diagnosed with autism spectrum disorders during the 2012 International Meeting for Autism Research.
IntegraGen announced today financial results for the year ending December 31, 2011.
IntegraGen, Inc. Names Michael Dresner National Sales Director
Cambridge, MA (April 17, 2012) - IntegraGen, Inc., a biotechnology company dedicated to molecular biomarker discovery, has named Michael E. Dresner National Sales Director. He will be responsible for IntegraGen's sales efforts in the U.S. associated with the ARISk™ Autism Risk Assessment Test.
Evry (France), April 27, 2011. IntegraGen announced that OSEO (the French state innovation agency) had awarded a total of €1.6 million in financial support to a collaborative project with the French National Institute of Health and Medical Research (INSERM). The financial support covers a 3-year period and will be supplied by OSEO as an interest-free loan that will be repayable from 2015 onwards if the project is successful.
The project (to be performed in collaboration with INSERM units U674 and U775) is notably based on promising research themes identified during the Carte d'Identité des Tumeurs ("Tumor ID Card") program funded by the French National League Against Cancer. The collaboration aims at developing
The project (to be performed in collaboration with INSERM units U674 and U775) is notably based on promising research themes identified during the Carte d'Identité des Tumeurs ("Tumor ID Card") program funded by the French National League Against Cancer. The collaboration aims at developing.
IntegraGen announced today that it has entered into an exclusive licensing agreement with The Johns Hopkins University and Massachusetts General Hospital to commercialize genetic tests that identify children at risk for autism which include a mutation to the Jumonji, AT Rich Interactive Domain 2 (JARID2) gene.
EVRY (FRANCE) - APRIL 11, 2011 - IntegraGen, a French biotechnology company dedicated to gene discovery and the development of molecular diagnostic products and services, announced today that it has entered into an exclusive licensing agreement with The Johns Hopkins University and Massachusetts General Hospital to commercialize genetic tests that identify children at risk for autism which include a mutation to the Jumonji, AT Rich Interactive Domain 2 (JARID2) gene.